Intestinal Proteins as Safe CAR-T Cell Therapy Targets for GI Cancers
Time: 1:10 pm
day: Day One
Details:
- Describe GUCY2C, a compartmentalized intestinal protein that may be targetable in GI cancers
- Address preclinical safety and efficacy data of GUCY2C-directed CAR-T cell therapies
- Review translational and clinical manufacturing plans as well as clinical trial design
